GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (FRA:AT2) » Definitions » Cyclically Adjusted Revenue per Share

Atara Biotherapeutics (FRA:AT2) Cyclically Adjusted Revenue per Share : €0.00 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Atara Biotherapeutics Cyclically Adjusted Revenue per Share?

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Atara Biotherapeutics's adjusted revenue per share for the three months ended in Mar. 2024 was €0.179. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Atara Biotherapeutics's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-14), Atara Biotherapeutics's current stock price is €0.48. Atara Biotherapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €0.00. Atara Biotherapeutics's Cyclically Adjusted PS Ratio of today is .

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Atara Biotherapeutics was 12.26. The lowest was 0.68. And the median was 4.47.


Atara Biotherapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Atara Biotherapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Cyclically Adjusted Revenue per Share Chart

Atara Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.39 0.30

Atara Biotherapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.33 0.33 0.30 -

Competitive Comparison of Atara Biotherapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Atara Biotherapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Cyclically Adjusted PS Ratio falls into.



Atara Biotherapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Atara Biotherapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.179/129.4194*129.4194
=0.179

Current CPI (Mar. 2024) = 129.4194.

Atara Biotherapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 0.000 105.998 0.000
201903 0.000 107.251 0.000
201906 0.000 108.070 0.000
201909 0.000 108.329 0.000
201912 0.000 108.420 0.000
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.000 109.897 0.000
202103 0.033 111.754 0.038
202106 0.035 114.631 0.040
202109 0.049 115.734 0.055
202112 0.069 117.630 0.076
202203 0.066 121.301 0.070
202206 0.479 125.017 0.496
202209 0.044 125.227 0.045
202212 0.002 125.222 0.002
202303 0.011 127.348 0.011
202306 0.008 128.729 0.008
202309 0.019 129.860 0.019
202312 0.036 129.419 0.036
202403 0.179 129.419 0.179

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Atara Biotherapeutics  (FRA:AT2) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Atara Biotherapeutics was 12.26. The lowest was 0.68. And the median was 4.47.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Atara Biotherapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics (FRA:AT2) Business Description

Industry
Traded in Other Exchanges
Address
2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Atara Biotherapeutics (FRA:AT2) Headlines

No Headlines